8-K filed Aug 6, 2026 at 07:03 ET
Evolent Health reported Q2 2026 revenue of $652.5M, up 46.9% YoY, but GAAP EPS was -$0.25, a miss vs the -$0.10 Street consensus. The company raised its full-year 2026 revenue guidance to $2.6-$2.7B and tightened its Adjusted EBITDA range to $120-$135M, while providing a bullish 2027 outlook of >25% revenue growth and $150M+ Adjusted EBITDA. However, the Medical Expense Ratio (MER) surged to 95.3% from 84.9% a year ago, signaling significant margin pressure in the Performance Suite, and operating cash flow remained negative.